Bronchodilator Drugs - Nordics

Nordics

The market of Bronchodilator Drugs market in the Nordics is expected to witness a significant rise in revenue.
According to projections, the revenue is set to reach a substantial amount of US$0.36bn by the year 2024.
This growth is driven by an anticipated annual growth rate (CAGR 2024-2029) of 3.13%, resulting in a market volume of US$0.42bn by 2029.
When compared to other countries, United States is poised to generate the highest revenue in this market, amounting to a staggering US$17,340.00m in the year 2024.
In the Nordics, there is a growing demand for bronchodilator drugs due to the high prevalence of respiratory diseases in the region.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Bronchodilator drugs market in Nordics is witnessing significant growth owing to the increase in the prevalence of respiratory diseases in the region.

Customer preferences: Patients in the Nordics region are more inclined towards adopting advanced treatment options for respiratory diseases. The demand for bronchodilator drugs is increasing as they provide immediate relief to patients suffering from bronchospasm. Additionally, the growing geriatric population in the region is also driving the demand for bronchodilator drugs.

Trends in the market: The bronchodilator drugs market in Nordics is witnessing a shift towards combination therapies that offer better efficacy and convenience to patients. The market is also witnessing the development of novel formulations of bronchodilator drugs that provide sustained relief to patients. Moreover, the market is also witnessing the adoption of digital technologies that help in the management of respiratory diseases.

Local special circumstances: The Nordics region is witnessing an increase in the prevalence of respiratory diseases owing to factors such as air pollution, smoking, and the growing geriatric population. Additionally, the region has a well-established healthcare infrastructure and a high level of healthcare expenditure, which is driving the growth of the bronchodilator drugs market.

Underlying macroeconomic factors: The Nordics region has a stable economy and a high level of per capita income, which is driving the growth of the healthcare sector in the region. Moreover, the region has a well-developed pharmaceutical industry that is investing in the development of novel formulations of bronchodilator drugs. The region is also witnessing an increase in the adoption of digital technologies in the healthcare sector, which is driving the growth of the bronchodilator drugs market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.